Track Themis Medicare Limited — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Themis Medicare Limited THEMISMED.NS · Stock Open Themis Medicare Limited in new tab

102.01 INR
P/E
23.72
EPS
4.33
Yield
0.50%
Safety Score
37
P/B
2.38
ROE
0.29
Beta
0.67
Loading chart...
Key Metrics
Earnings dateMay 18, 2026
P/E23.72
EPS4.33
Book Value43.06
Price to Book2.38
Debt/Equity25.11
% Insiders55.963%
Growth
Revenue Growth-0.11%
Earnings Growth17.17%
Dividend
Dividend Yield0.50%
Annual dividends0.50 INR
Ex-Div. DateSept. 23, 2026
Payout11.51%

DCF valuation

Model fair value for Themis Medicare Limited (THEMISMED.NS)
Result
Sign in to run the valuation for THEMISMED.NS.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–

Themis Medicare Limited Logo Themis Medicare Limited Analysis (THEMISMED.NS)

India Health Care Official Website Stock

Is Themis Medicare Limited a good investment? Themis Medicare Limited (THEMISMED.NS) is currently trading at 102.01 INR.

In terms of valuation, the stock trades at a P/E ratio of 23.72. This valuation is generally in line with the broader market.

Earnings Schedule: Themis Medicare Limited is expected to release its next earnings report on May 18, 2026.

For income investors, Themis Medicare Limited pays a dividend yield of 0.50%. With a payout ratio of 12%, the dividend appears sustainable.

Investor FAQ

Does Themis Medicare Limited pay a dividend?

Yes, it pays an annual dividend of 0.50 INR (0.50% yield).

What asset class is Themis Medicare Limited?

Themis Medicare Limited is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be May 18, 2026. The company currently has a trailing EPS of 4.33.

Company Profile

Themis Medicare Limited, together with its subsidiaries, manufactures and sells pharmaceutical products in India and internationally. It provides active pharmaceutical ingredients (APIs) and formulations used in various therapeutic areas, including analgesic and anti-inflammatory, analgesic and antispasmodic, analgesics, anesthesia, antacid-antiflatulent, anti-fungal, antibiotic, anti-diabetic, anti-emetic, anti-hypertensive, anti-allergic and anti-inflammatory, anti-allergic and appetite stimulant, anticoagulant, antifibrolytic, antimalarial, anti-muscarinic, antioxidant, calcium, cardiovascular, corticosteroid, electrolytes, expectorant, haematinic, hemostatic agent, hemostatic agent with anesthetic, hormones, immunomodulator with anti-viral, muscle relaxant, narcotic analgesic, neuropathy, nutraceuticals, PPI, probiotic, reversal for muscle relaxant, sedatives, skeletal muscle relaxant, skeletal muscle relaxant and analgesic and anti-inflammatory, vasopressors, vitamins, and weight management. The company was formerly known as Themis Chemicals and changed its name to Themis Medicare Limited in 2001. Themis Medicare Limited was founded in 1952 and is headquartered in Mumbai, India.

Exchange Ticker
NSI (India) THEMISMED.NS
Trades
Dividend Yield
0.50%
Annual Dividends
0.50INR
Next Ex. Div Date
Sept. 23, 2026
Payout Ratio
11.51%
Dividend History paid per year (INR)
Historical Dividends
Year Total Dividends
▸2027
0.50 INR
Sept. 30, 2027 (estimated) 0.5000
▸2026
0.50 INR
Sept. 30, 2026 0.5000
▸2025
0.50 INR
Oct. 12, 2025 0.5000
▸2024
0.50 INR
Aug. 3, 2024 0.5000
▸2023
5.00 INR
Oct. 9, 2023 5.0000
▸2022
5.00 INR
Oct. 19, 2022 5.0000
▸2021
4.30 INR
Oct. 18, 2021 4.3000
▸2020
1.75 INR
Oct. 28, 2020 1.7500
▸2011
3.00 INR
Aug. 29, 2011 3.0000
▸2010
3.00 INR
July 25, 2010 3.0000
▸2008
2.50 INR
Sept. 1, 2008 2.5000
▸2007
2.00 INR
Sept. 14, 2007 2.0000
Upcoming Dividends
Name Payment Date Status Amount
Themis Medicare Limited Sep 30, 2026 0.5 INR
Stock Splits
Split Date Split Ratio to 1
Oct. 10, 2023 10:1
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion